August 25, 2020
Via EDGAR Transmission
Division of Corporation Finance
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attn: Jeffrey Gabor
| Re: | Verona Pharma plc |
| Registration Statement on Form F-1 | |
| Filed August 25, 2020 | |
| Registration No. 333- 247928 |
Dear Mr. Gabor:
In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request the acceleration of the effective date of the above-referenced Registration Statement so that it will become effective on August 27, 2020 at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, or at such later time as Verona Pharma plc (the “Company”) or its counsel may request via telephone call to the staff. Please contact Peter Handrinos of Latham & Watkins LLP, counsel to the Company, at (617) 948-6060, or in his absence, Nathan Ajiashvili at (212) 906-2916, to provide notice of effectiveness, or if you have any other questions or concerns regarding this matter.
| Sincerely yours, | ||
| Verona Pharma plc | ||
| By: | /s/ David Zaccardelli, Pharm.D. | |
| David Zaccardelli, Pharm.D. | ||
| President and Chief Executive Officer | ||
| cc: | Peter N. Handrinos, Latham & Watkins LLP |
| Nathan Ajiashvili, Latham & Watkins LLP |
